| __timestamp | Arrowhead Pharmaceuticals, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 16758000 |
| Thursday, January 1, 2015 | 34718089 | 17793000 |
| Friday, January 1, 2016 | 40998209 | 18761000 |
| Sunday, January 1, 2017 | 32022880 | 19287000 |
| Monday, January 1, 2018 | 19110051 | 18707000 |
| Tuesday, January 1, 2019 | 26556257 | 20893000 |
| Wednesday, January 1, 2020 | 52275890 | 25678000 |
| Friday, January 1, 2021 | 80981000 | 29665000 |
| Saturday, January 1, 2022 | 124431000 | 43628000 |
| Sunday, January 1, 2023 | 90932000 | 69135000 |
| Monday, January 1, 2024 | 98761000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Arrowhead Pharmaceuticals and Geron Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Arrowhead's SG&A expenses surged by approximately 400% from 2014 to 2023, peaking in 2022. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Geron Corporation's SG&A expenses grew at a steadier pace, with a notable increase of around 300% by 2023. However, data for 2024 is missing, leaving room for speculation on future trends. These patterns highlight Arrowhead's rapid growth strategy compared to Geron's more conservative approach. As the biotech sector evolves, monitoring these financial strategies offers insights into each company's operational focus and market positioning.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Geron Corporation
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Geron Corporation
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation